Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 13 Lung Neoplasms 12 Carcinoma, Non-Small-Cell Lung 7 Breast Neoplasms 7 Carcinoma, Renal Cell 6 Urinary Bladder Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Neuroblastoma 4 Glioblastoma 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Small Cell Lung Carcinoma 3 Oropharyngeal Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Mouth Neoplasms 3 Melanoma 3 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Ganglioneuroblastoma 3 Disease 3 Carcinoma, Hepatocellular 3 Carcinoma 3 Ureteral Neoplasms 2 Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Medulloblastoma 2 Lymphoma, Mantle-Cell 2

Interventions

Carboplatin 5 Pemetrexed 4 pembrolizumab 3 Paclitaxel 2 Gemcitabine 2 Cisplatin 2 pralsetinib 1 camrelizumab 1 Vinorelbine 1 TNFSF10 protein, human 1 Nivolumab 1 Mediastinoscopy 1 Magnetic Resonance Spectroscopy 1 Injections 1 Docetaxel 1 Bronchoscopy 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Bronchogenic × Magnetic Resonance Spectroscopy × Clear all

NCT00652769 2017-11-01

BOOST

University College London Hospitals

Phase 3 Completed

Carcinoma, Bronchogenic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡